371 related articles for article (PubMed ID: 19888523)
1. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes.
Vardi M; Laor A; Bitterman H
Thromb Haemost; 2009 Nov; 102(5):879-86. PubMed ID: 19888523
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
Kearon C
Curr Opin Pulm Med; 2007 Sep; 13(5):398-402. PubMed ID: 17940484
[TBL] [Abstract][Full Text] [Related]
3. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
Hull RD; Pineo GF
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
[TBL] [Abstract][Full Text] [Related]
4. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
5. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism--an overview.
Bernardi E; Piccioli A; Oliboni G; Zuin R; Girolami A; Prandoni P
Thromb Haemost; 2000 Jul; 84(1):22-6. PubMed ID: 10928464
[TBL] [Abstract][Full Text] [Related]
6. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
Prandoni P; Carnovali M; Marchiori A;
Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
[TBL] [Abstract][Full Text] [Related]
8. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
10. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.
Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
Arch Intern Med; 1997 Nov; 157(20):2317-21. PubMed ID: 9361572
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
12. [Drug therapy of deep venous thrombosis].
Bounameaux H
Ther Umsch; 1996 Apr; 53(4):272-6. PubMed ID: 8658349
[TBL] [Abstract][Full Text] [Related]
13. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives].
Prandoni P; Simioni P; Pagnan A
Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718
[TBL] [Abstract][Full Text] [Related]
15. Initial treatment of venous thromboembolism.
Becattini C; Agnelli G; Emmerich J; Bura A; Weitz JI
Thromb Haemost; 2006 Sep; 96(3):242-50. PubMed ID: 16953263
[TBL] [Abstract][Full Text] [Related]
16. Unfractionated heparin therapy in infants and children.
Newall F; Johnston L; Ignjatovic V; Monagle P
Pediatrics; 2009 Mar; 123(3):e510-8. PubMed ID: 19221154
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
18. Guideline update. VTE disease: which agents, and when.
Holten KB; Merok J
J Fam Pract; 2009 Mar; 58(3):E1. PubMed ID: 19284934
[No Abstract] [Full Text] [Related]
19. [-Anticoagulant drugs-].
Gulba DC
Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
[TBL] [Abstract][Full Text] [Related]
20. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.
Myzienski AE; Lutz MF; Smythe MA
Pharmacotherapy; 2010 Mar; 30(3):324. PubMed ID: 20180615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
